1391 |
Leaflet Thrombosis, Is It Clinically Relevant? |
Duk-Woo Park |
Apr. 08. 22 |
1390 |
Long-Term Antithrombotic Strategy in PCI and AF Patients: Insights From the AFIRE Trial |
Satoshi Yasuda |
Apr. 08. 22 |
1389 |
DAPT Duration and NOAC Selection in the Afib-PCI Patient |
Renato D. Lopes |
Apr. 08. 22 |
1388 |
DAPT Study vs. Contemporary Trials: How Can We Reduce the Knowledge Gap? |
Robert W. Yeh |
Apr. 08. 22 |
1387 |
Optimal Antithrombotic Therapy After PCI in Asia (Japan): Why We Are Going Our Own Way? |
Takeshi Kimura |
Apr. 08. 22 |
1386 |
Role of CABG in Multivessel Disease |
Jack H. Boyd |
Apr. 08. 22 |
1385 |
Role of PCI in Multivessel CAD: What Do the New Guidelines Say? |
William F. Fearon |
Apr. 08. 22 |
1384 |
CABG Remains the Best Therapy for Most Patients With Left Main Disease |
John D. Puskas |
Apr. 08. 22 |
1383 |
Left Main Revascularization: Data Supports PCI in Most Cases |
Gregg W. Stone |
Apr. 08. 22 |
1382 |
Most Updated IPD Meta-Analysis for LM Revascularization |
Brian Bergmark |
Apr. 08. 22 |